HCTI on Nasdaq
Healthcare Triangle, Inc.
Combined with our software and solutions, our services provide clients with an end-to-end partnership for their technology innovation.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Borqs Technologies, Inc., Super League Enterprise, Inc. or TuSimple, or pick any stock.
- TickerHCTI on Nasdaq2
- IndustryServices-Computer Integrated Systems Design2
- HeadquartersPleasanton, United States2
- Incorporated inDE3
- Business address7901 Stoneridge Drive, Suite 210, Pleasanton, Ca 945883
- Filer category, Emerging growth company3
- Legal formCorporation2
- LEI549300KKBM83T87VHO352
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O HARVARD BUSINESS SERVICES, INC., 19958 Lewes, United States2
- Registered withDivision of Corporations, Department of State, 79496342
See how the biggest companies compare on our leaderboards
Combined with our software and solutions, our services provide clients with an end-to-end partnership for their technology innovation.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
8890.6%Gross margin5
-70.5%Operating margin5
-68.2%Net margin5
18.8%Revenue growth, 20255
-95.3%Return on equity5
-$16.5MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Software Services brought in 58% of the revenue Healthcare Triangle, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Software Services | $4.7M | $8.3M |
| Managed Services And Support | $6.7M | $5.4M |
| Corporate And Others | $288.0K | $278.0K |
| Corporate Others | $288.0K | $278.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue86¢$12.0M
- Research and development4¢$536.0K
- Other costs6¢$787.0K
- Interest4¢$567.0K
Out of $13.9M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net revenue | $13.9M | $11.7M |
| Cost of revenue (exclusive of depreciation and amortization shown separately below) | $12.0M | $8.8M |
| Gross margin | $1.9M | $2.9M |
| Sales and marketing | $3.1M | $2.2M |
| General and administrative | $7.3M | $4.0M |
| Research and development | $536.0K | $429.0K |
| Bad debts expense | $17.0K | $170.0K |
| Depreciation and amortization | $705.0K | $889.0K |
| Total operating expenses | $11.7M | $7.6M |
| Loss from operations | -$9.8M | -$4.8M |
| Other income | $857.0K | $7.0K |
| Changes in fair value | $41.0K | |
| Forex loss | -$18.0K | |
| Interest expense | -$567.0K | -$1.2M |
| Loss before income tax | -$9.5M | -$6.0M |
| Provision for income tax | -$12.0K | |
| Net loss | -$9.5M | -$6.0M |
| Foreign currency translation gain | $11.0K | |
| Deemed dividend | -$7.4M | |
| Comprehensive loss | -$9.5M | -$13.4M |
| Stockholders | -$9.4M | -$13.4M |
| Non-controlling interest | -$37.0K | |
| Stockholders (in Dollars per share) | -$152.30 | -$16,909.30 |
| Stockholders - diluted (in Dollars per share) | -$152.30 | -$16,909.30 |
| Non-controlling interest - basic (in Dollars per share) | -$1 | |
| Non-controlling interest - diluted (in Dollars per share) | -$1 | |
| Basic (in Shares) | 61.9K shares | 353 shares |
| Diluted (in Shares) | 61.9K shares | 353 shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $7.6M | $20.0K | ||
| Accounts receivable, net | $2.1M | $1.1M | ||
| Other current assets | $3.5M | $322.0K | ||
| Total current assets | $13.2M | $1.5M | ||
| Furniture and equipment, net | $5.0K | $12.0K | ||
| Goodwill | $2.9M | $2.9M | ||
| Other intangible assets, net | $2.8M | |||
| Advances | $3.8M | $497.0K | ||
| Total assets | $22.7M | $2.0M | ||
| Accounts payable | $744.0K | $2.5M | ||
| Short-term borrowing | $10.7M | $2.6M | ||
| Other current liabilities | $1.3M | $1.4M | ||
| Contingent consideration | $500.0K | |||
| Total current liabilities | $12.8M | $7.1M | ||
| Common stock, par value $0.00001; 2,000,000,000 authorized, 142,426 and 380 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively | $11.0K | |||
| Non-controlling interest | -$37.0K | |||
| Additional paid-in capital | $45.5M | $21.0M | ||
| Accumulated deficit | -$43.0M | -$33.6M | ||
| Total stockholders equity (deficit) | $9.9M | -$5.1M | -$1.4M | |
| Total liabilities and stockholders equity | $22.7M | $2.0M | ||
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in Shares) | 10.0M shares | 10.0M shares | ||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in Shares) | 2.0B shares | 2.0B shares | ||
| Common stock, shares issued (in Shares) | 142.4K shares | 380 shares | ||
| Common stock, shares outstanding (in Shares) | 142.4K shares | 380 shares |
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $7.6M | $20.0K | ||
| Accounts receivable, net | $2.1M | $1.1M | ||
| Other current assets | $3.5M | $322.0K | ||
| Total current assets | $13.2M | $1.5M | ||
| Furniture and equipment, net | $5.0K | $12.0K | ||
| Goodwill | $2.9M | $2.9M | ||
| Other intangible assets, net | $2.8M | |||
| Advances | $3.8M | $497.0K | ||
| Total assets | $22.7M | $2.0M | ||
| Accounts payable | $744.0K | $2.5M | ||
| Short-term borrowing | $10.7M | $2.6M | ||
| Other current liabilities | $1.3M | $1.4M | ||
| Contingent consideration | $500.0K | |||
| Total current liabilities | $12.8M | $7.1M | ||
| Common stock, par value $0.00001; 2,000,000,000 authorized, 142,426 and 380 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively | $11.0K | |||
| Non-controlling interest | -$37.0K | |||
| Additional paid-in capital | $45.5M | $21.0M | ||
| Accumulated deficit | -$43.0M | -$33.6M | ||
| Total stockholders equity (deficit) | $9.9M | -$5.1M | -$1.4M | |
| Total liabilities and stockholders equity | $22.7M | $2.0M | ||
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in Shares) | 10.0M shares | 10.0M shares | ||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in Shares) | 2.0B shares | 2.0B shares | ||
| Common stock, shares issued (in Shares) | 142.4K shares | 380 shares | ||
| Common stock, shares outstanding (in Shares) | 142.4K shares | 380 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$9.5M | -$6.0M |
| Depreciation and amortization | $705.0K | $889.0K |
| Bad debt expense | $17.0K | $170.0K |
| Amortization of debt discount | $223.0K | $979.0K |
| Conversion fees | $56.0K | |
| Stock compensation expenses | $451.0K | $87.0K |
| Net unrealized exchange gain | -$27.0K | |
| Expenses settled through equity | $393.0K | $22.0K |
| Interest expense | $567.0K | |
| Other income | -$685.0K | -$7.0K |
| Accounts receivable | -$913.0K | $2.3M |
| Other current assets | -$3.1M | $502.0K |
| Advances | -$3.3M | -$193.0K |
| Accounts payable and accrued expenses | -$1.5M | $593.0K |
| Other current liabilities | $265.0K | -$525.0K |
| Contingent consideration | -$100.0K | |
| Net cash used in operating activities | -$16.5M | -$1.1M |
| Purchase of furniture and equipment | -$6.0K | |
| Acquisition of intangible assets | -$1.5M | |
| Increase in other non-current assets | -$247.0K | |
| Net cash used in investing activities | -$1.8M | |
| Proceeds from / (Repayment of) short term borrowing | $9.4M | -$1.1M |
| Proceeds from equity issuance | $17.0M | $956.0K |
| Interest paid | -$567.0K | |
| Net cash provided by financing activities | $25.9M | -$133.0K |
| Net increase/(decrease) in cash and cash equivalents | $7.6M | -$1.2M |
| Interest | $121.0K | |
| Income tax | $12.0K | |
| Conversion of debt to common stock | $2.6M | $1.2M |
| Settlement of contingent consideration | $400.0K | |
| Common stock issued for acquisition | $4.6M | |
| Issuance of Series B preferred stock in connection with acquisition of customer contracts from a common control entity | $7.4M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Healthcare Triangle, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2025
- Chief executive officerSuresh Venkatachari Oct 29, 2021 to Nov 14, 202212
- Chief financial officerThyagarajan Ramachandran Dec 6, 2021 to Apr 2, 202513
Board members and other officers (17)
- Head of M&AShibu Kizhakevilayil Apr 2, 2025 to Apr 2, 202514
- Head of Strategic PartnershipLakshmanan Kannappan Mar 21, 2023 to Apr 2, 202515
- Chief Technology OfficerMogli Sudish Oct 25, 2021 to Feb 14, 202216
- Vice President, SalesAnand Kumar Oct 29, 2021 to Mar 21, 202317
- Vice President, FinanceJames Michael Gill Dec 6, 2021 to Feb 14, 202218
- Board memberMohammad Jainal Bhuiyan Feb 6, 2023 to Mar 13, 202419
- Board memberPaige Heaphy Feb 6, 2023 to Feb 6, 202320
- Board memberRonald W. McClurg Feb 6, 2023 to Mar 13, 202421
- Board memberRoy Sookhoo Feb 6, 2023 to Feb 6, 202322
- Board memberJeffrey S. Mathiesen Apr 1, 2022 to Aug 22, 202223
- Board memberLakshmanan Kannappan Oct 25, 2021 to Mar 21, 202324
- Board memberShibu Kizhakevilayil Oct 25, 2021 to Apr 2, 202525
- Board memberVivek Prakash Oct 25, 2021 to Feb 14, 202226
- Board memberSuresh Venkatachari Oct 29, 2021 to Nov 14, 202212
- Board memberBrendan Gallagher Dec 6, 2021 to Feb 14, 202227
- Board memberDavid A. Rosa Dec 6, 2021 to Mar 13, 202428
- Board memberApril Bjornstad Dec 8, 2021 to Aug 22, 202229
Named in SEC Form D filings
People the company listed in its private-offering notices.
Timeline
Filings
240 filings to the SEC since October 2021: 8 annual reports, 16 quarterly reports, 68 major events, 50 insider forms, 8 large holders, 2 private raises, 88 other. The latest 20:
- Oct 13, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
- Oct 2, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
- Oct 2, 20268-K CURRENT REPORT EDGAR
- Sep 30, 2026EFFECT EDGAR
- Sep 25, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Sep 25, 20268-K CURRENT REPORT EDGAR
- Sep 8, 20268-K CURRENT REPORT EDGAR
- Aug 13, 202610-Q QUARTERLY REPORT EDGAR
- Jul 29, 20268-K CURRENT REPORT EDGAR
- Jul 20, 20268-K CURRENT REPORT EDGAR
- Jul 16, 2026424B3 PROSPECTUS EDGAR
- Jul 15, 2026EFFECT EDGAR
- Jul 10, 2026S-1 REGISTRATION STATEMENT EDGAR
- Jul 9, 2026RW WITHDRAWAL REQUEST EDGAR
- Jul 6, 2026S-3 REGISTRATION STATEMENT EDGAR
- Jun 26, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
- Jun 26, 20268-K CURRENT REPORT EDGAR
- Jun 16, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
- Jun 16, 2026D EDGAR
- Jun 15, 20268-K CURRENT REPORT EDGAR
The 240 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Orca Capital AGSCHEDULE 13G/A, 2 filings Mar 2, 2026 to Mar 5, 202631
- East West Capital, LLCSCHEDULE 13G/A, 2 filings Mar 7, 2025 to Dec 15, 202532
- L1 Capital Global Opportunities Master Fund, Ltd.SCHEDULE 13G/A, 2 filings Feb 4, 2025 to Aug 14, 202533
- SECUREKLOUD TECHNOLOGIES, INC.SC 13D/A, 2 filings Oct 25, 2021 to Oct 26, 202134
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Bank Of Montreal /can/ | 20,000 | $36.2K | 0.0% | +10,000 |
| Geode Capital Management, LLC | 11,975 | $21.7K | 0.0% | −620 |
| UBS Group AG | 8,859 | $16.0K | 0.0% | −31,856 |
| Tower Research Capital LLC (TRC) | 1,314 | $2.4K | 0.0% | +520 |
| Vanguard Capital Management LLC | 859 | $1.6K | 0.0% | No change |
| Barclays PLC | 310 | $561 | 0.0% | New |
| Jpmorgan Chase & Co | 20 | $38 | 0.0% | New |
| Danske Bank A/s | 1 | $2 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARShibu Kizhakevilayil, Head of M&A
- 15
- 16
- 17SEC EDGARAnand Kumar, Vice President, Sales
- 18
- 19
- 20SEC EDGARPaige Heaphy, Board member
- 21SEC EDGARRonald W. McClurg, Board member
- 22SEC EDGARRoy Sookhoo, Board member
- 23SEC EDGARJeffrey S. Mathiesen, Board member
- 24SEC EDGARLakshmanan Kannappan, Board member
- 25SEC EDGARShibu Kizhakevilayil, Board member
- 26SEC EDGARVivek Prakash, Board member
- 27SEC EDGARBrendan Gallagher, Board member
- 28SEC EDGARDavid A. Rosa, Board member
- 29SEC EDGARApril Bjornstad, Board member
- 30
- 31
- 32
- 33
- 34